Primary Peritoneal Carcinoma
147
17
32
63
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
32 trials with published results (22%)
Research Maturity
63 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.3%
21 terminated out of 147 trials
75.0%
-11.5% vs benchmark
10%
14 trials in Phase 3/4
51%
32 of 63 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 63 completed trials
Clinical Trials (147)
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
National Cancer Institute "Cancer Moonshot Biobank"
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Diet, Hepcidin, and Chemotherapy RDI
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers